BidaskClub upgraded shares of Natera (NASDAQ:NTRA) from a strong sell rating to a sell rating in a report released on Friday morning.

Several other equities research analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of Natera from a buy rating to a hold rating in a report on Wednesday, November 14th. Cowen reaffirmed a buy rating and issued a $30.00 price objective on shares of Natera in a report on Friday, November 9th. TheStreet downgraded shares of Natera from a c- rating to a d+ rating in a report on Tuesday, October 9th. JPMorgan Chase & Co. began coverage on shares of Natera in a report on Friday, October 5th. They issued a neutral rating and a $26.00 price objective for the company. Finally, Morgan Stanley upped their price objective on shares of Natera from $21.00 to $41.00 and gave the stock an overweight rating in a report on Friday, September 28th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $28.25.

NTRA stock traded down $0.72 during trading on Friday, hitting $16.97. The company had a trading volume of 458,109 shares, compared to its average volume of 700,611. The company has a market capitalization of $1.09 billion, a P/E ratio of -7.07 and a beta of 2.03. Natera has a fifty-two week low of $8.60 and a fifty-two week high of $29.62. The company has a quick ratio of 2.32, a current ratio of 2.44 and a debt-to-equity ratio of 1.30.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, November 8th. The medical research company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.03). The company had revenue of $65.30 million during the quarter, compared to analyst estimates of $66.42 million. Natera had a negative return on equity of 2,569.52% and a negative net margin of 58.00%. The business’s revenue for the quarter was up 16.8% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.51) EPS. Equities analysts anticipate that Natera will post -2.11 EPS for the current year.

In other Natera news, COO Steven Leonard Chapman sold 45,000 shares of the company’s stock in a transaction dated Tuesday, September 11th. The shares were sold at an average price of $25.16, for a total value of $1,132,200.00. Following the completion of the sale, the chief operating officer now directly owns 16,628 shares of the company’s stock, valued at approximately $418,360.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jonathan Sheena sold 166,667 shares of the company’s stock in a transaction dated Friday, September 14th. The shares were sold at an average price of $24.27, for a total transaction of $4,045,008.09. Following the completion of the sale, the insider now directly owns 481,975 shares of the company’s stock, valued at $11,697,533.25. The disclosure for this sale can be found here. Insiders sold a total of 2,014,988 shares of company stock valued at $48,674,710 over the last three months. 13.18% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of NTRA. Pacer Advisors Inc. acquired a new stake in Natera in the 3rd quarter valued at about $106,000. Point72 Hong Kong Ltd acquired a new stake in Natera during the 3rd quarter worth about $119,000. Quantbot Technologies LP acquired a new stake in Natera during the 3rd quarter worth about $135,000. State Board of Administration of Florida Retirement System acquired a new stake in Natera during the 2nd quarter worth about $200,000. Finally, Meeder Asset Management Inc. raised its holdings in Natera by 920.5% during the 3rd quarter. Meeder Asset Management Inc. now owns 8,399 shares of the medical research company’s stock worth $200,000 after buying an additional 7,576 shares during the period. 87.90% of the stock is owned by institutional investors.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Read More: Return on Equity (ROE)

Analyst Recommendations for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.